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Short summary 30 
Secondary malignancy post haematopoietic stem cell transplantation (HSCT) for 31 
malignant disorders is well recognized. There are very few published reports on 32 
malignancy post HSCT for Primary Immunodeficiency (PID). We report 12 cases 33 
of 944 patients, who developed non-PTLD malignancy post-HSCT for PID. 34 
 35 
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To the Editor 38 
 39 
Secondary malignancy post-haematopoietic stem cell transplantation 40 
(HSCT) for malignant disorders related to cytotoxic treatment, radiotherapy and 41 
pre-existing genetic pre-disposition, is well recognized. Data regarding the 42 
incidence of malignancy in normal children and in those post-HSCT for 43 
haematological disorders can be found in the online repository. 44 
Some non-malignant disorders may predispose to malignancy as seen in 45 
cases with Fanconi anaemia developing squamous cell carcinoma of head, neck 46 
and anogenital mucosal surfaces particularly if graft-versus-host disease (GVHD) 47 
occurs. Post transplant lymphoproliferative disorders (PTLDs) usually in 48 
association with Epstein Barr virus (EBV), may occur after HSCT for any 49 
underlying diagnosis, usually within 2 years post-transplant, most often 50 
associated with T-lymphocyte depletion (TCD) and intense immunosuppression, 51 
for example in the context of GVHD1. Data are sparse on occurrence of non-PTLD 52 
malignancy post-HSCT in patients with primary immunodeficiencies (PID).  PID 53 
are an heterogenous group of disorders affecting the regulation and function of 54 
the immune system. To date, more than 300 genetic defects cause different 55 
disease phenotypes. It is estimated that the risk of malignancy in children with 56 
PID is about 4%, 10 000 times greater than in age-matched controls2. HSCT can 57 
cure PID, and reduce the risk of malignancy, but it is unknown whether HSCT 58 
itself might increase the incidence of malignancy compared to the normal 59 
population. Fifty-two post HSCT malignancies were confirmed in a large study of 60 
2266 patients with PID including 45 PTLDs. Three patients developed 61 
myelodysplastic syndrome (MDS) all of whom had received TBI and TCD grafts, 1 62 
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patient developed acute myeloid leukaemia (AML) and 3 developed solid 63 
tumours giving an incidence of 0.3% of non-PTLD malignancy3.  Six malignancies 64 
were reported from 318 patients who underwent allogeneic HSCT for non-65 
malignant disorders, including 2 solid tumours in 130 patients with PID (1 with 66 
Severe combined immunodeficiency (SCID) and 1 with Chronic granulomatous 67 
disease)4.  68 
We report a retrospective analysis of 944 children who underwent HSCT 69 
for PID at two UK centers. Diagnosis, timing and type of transplant, conditioning 70 
regimen, GVHD, viral reactivation, type of malignancy and outcome were 71 
recorded. 72 
Twelve patients (1.27%) developed non-PTLD malignancy (Table 1). 73 
Median interval from HSCT to malignancy diagnosis was 3.75 years (3 months – 74 
11.2 years). Mean age at transplant in those who developed malignancy was 85 75 
months (4 months – 204 months). Four received an HLA matched sibling donor 76 
(MSD) bone marrow (BM) transplant, 4 had matched and 1 mismatched 77 
unrelated donor BM, 2 matched unrelated donor PBSC and 1 matched cord blood 78 
transplant.  79 
None of the patients received radiotherapy. Seven had reduced intensity 80 
conditioning (RIC) with fludarabine and melphalan, 3 had reduced toxicity 81 
myeloablative conditioning with treosulfan and fludarabine, 2 had myeloablative 82 
doses of busulfan, 1 with cyclophosphamide(n=1), the other with fludarabine 83 
(n=1). Ten received serotherapy with Alemtuzumab and 2 MSD recipients had no 84 
serotherapy. All patients received cyclosporine based GVHD prophylaxis either 85 
alone (n=2) or with  mycophenolate mofetil ( P1-5,7,8 and 11) or methotrexate 86 
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(P9,P12) . 87 
Two patients died from malignancy. The rest were successfully treated 88 
and are alive with a median follow up of 13.2 years ( 2 years 1 mth – 18 years). 89 
Both P1 and P12 had lost donor engraftment in whole blood or B 90 
cell/myeloid subsets before the onset of Philadelphia positive acute 91 
lymphoblastic leukemia (P1) and Juvenile Myelomonocytic Leukemia (P12) 92 
respectively. Both malignancies were confirmed to be recipient in origin. Both 93 
had an underlying immune defect that predisposes to malignancy (RAG 2 in P1, 94 
Griscelli syndrome in P12). This poses the question as to whether full donor 95 
chimerism might have abolished this risk. Alternatively recipient stem cells 96 
surviving chemotherapy may have acquired genotoxic insults.  97 
P9 developed Acute Myeloid Leukemia (AML M4) 11 years post-HSCT 98 
which is uncommon. Unfortunately, it was undetermined whether leukemic cells were 99 
donor or recipient origin. A European Bone Marrow Transplantation group survey 100 
estimated incidence of MDS/AML to be 1.2:1000 transplants, mostly occurring 101 
within 4 years of HSCT (See OR)E6. Multiple hit theory postulates that donor cells 102 
already acquired a first hit in the donor and additional hits are acquired in the host 103 
marrow microenvironment. Viral persistence, disturbed immunosurveillance and 104 
accelerated telomere shortening may also be contributory6,7.  105 
P2 and P5 developed parotid muco-epidermoid carcinoma (MEC) at 6 and 106 
3 years post-HSCT.  Interestingly both experienced oral cGVHD and had  107 
prolonged HHV6 viraemia post-HSCT. Data link parotid MEC to prolonged CMV 108 
infection, which remains dormant in the salivary glands8. Presence of HHV6 in an 109 
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immunocompromised host might have played a role in the development of this 110 
rare tumour. 111 
P7 had fungal granuloma pre-transplant, received voriconazole 112 
throughout transplant and developed actinic keratosis, a pre-malignant 113 
condition and later squamous cell carcinoma of the lower leg and auricular basal 114 
cell carcinoma. A retrospective study confirmed the association between 115 
voriconazole and the development of squamous cell carcinoma post-allogenic 116 
HSCT9. 117 
P8 and P11 had a family history of solid tumor suggesting possible genetic 118 
factors. P2,5,7 and 11 experienced acute GVHD and  P11 additionally 119 
experienced chronic GVHD. Immune dysregulation post-HSCT might have played 120 
a role in the failure of T-lymphocyte checkpoint for tumors. 121 
Whilst early haematological malignancies likely relate to the pre-existing 122 
genotype in remaining recipient cells, most of our patients developed late rare 123 
solid tumors. Understanding the pathogenesis of solid tumors after HSCT is 124 
limited, but intensive cytotoxic conditioning with defective DNA repair of 125 
persisting stem cells/stromal cells, viral infection and immunosuppression may 126 
be implicated. All patients in this cohort received alkylating agents during 127 
conditioning. These agents induce chromosomal breakage and possible 128 
malignant transformation. Over the last 15 years the use of RIC and reduced 129 
toxicity conditioning has increased but it is unknown whether this will reduce 130 
the risk of malignancy post-HSCT. Fludarabine-based conditioning, moderate-131 
severe chronic GVHD and chronic myeloproliferative or non-malignant disease 132 
are risk factors for second malignancy in adult patients5,6. Shimoni et al found no 133 
significant difference in the incidence of secondary malignancies in 931 adults 134 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
receiving myeloablative, reduced intensity or reduced toxicity conditioning and 135 
postulated that there may be synergistic effects of DNA damage from an 136 
alkylator added to fludarabine related inhibition of DNA repair used in reduced 137 
intensity or toxicity regimens6. 138 
In conclusion we report an incidence of 1.27% non-PTLD malignancy 139 
occurring in a large cohort of PID patients who received cytotoxic chemotherapy 140 
without radiotherapy for HSCT. This incidence is higher than that reported by  141 
Kamani et al. which may be due to the smaller number of patients. Underlying 142 
genetic disease, tissue distribution of genetic defect, GvHD, viral infections and 143 
extent of donor chimerism may be important factors that play a role in primary 144 
immunodeficiency patients developing secondary malignancies post-HSCT. 145 
Further studies are needed to evaluate risks but we support recommendations 146 
for life-long follow up for this population. 147 
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Table I. Patient characteristics 220 
Diagnosis 
Lineage 
specificity of 
gene defect 
Age at   
HSCT 
 (years) 
Conditioning 
Regimen 
Source of 
stem cells 
Chimerism 
T/B/Myeloid 
(%) 
Malignancy Interval 
post 
HSCT 
(years) 
Acute/ 
Chronic GVHD 
Auto-
immunity 
Viral 
react-
ivation 
Status 
1.RAG 2 SCID 
lymphocyte- 
specific 
0.3 T 36g/m2 
F 150mg/m2 
MSD BM 100/0/0 Ph+ Pre B ALL 2.5 No No No Died 
2.MHC I 
systemic 
13.6  F150mg/m2 
Mel140mg/m2 
AI 1mg/kg 
MUD BM 100/100/100 Parotid MEC 6  Acute Skin & 
oral GVHD 
No HHV6 Alive 
3.GATA 2  
systemic 
15.9  F150mg/m2 
Mel140g/m2 
Al 1 mg/kg 
MMUD BM 94/100/100 Toe Melanoma 6.9  No No No Alive 
4.JAK 3 SCID 
lymphocyte-
specific 
0.1 T36g/m2 
F150mg/m2 
Al 0.3mg/kg 
Matched 
UCB 
100/97/93 Right Occipital 
Ewing Sarcoma 
3.58  No No No Alive 
5.NFKB2  
systemic 
14  F150mg/m2 
Mel140mg/m2 
AI 1mg/kg 
MSD BM 100/100/100 Parotid MEC 3  Acute Skin 
Grade II and 
Liver Grade I 
GVHD + Oral 
GVHD 
No HHV6 Alive 
6.WAS 
hematopoietic 
17  F150mg/m2 
Mel140mg/m2 
Al 1mg/kg 
MUD BM 100/100/100 Squamous cell ca  
(gastrostomy site) 
0.25 No No EBV Alive 
7.X linked-CGD 
myeloid specific 
15  F160mg/m2 
Bu12.8mg/kg 
Al 1mg/kg 
MUD PBSC 100/100/100 Basal cell ca 
(ear) and left 
lower leg 
squamous cell 
carcinoma in situ 
4  Acute Skin 
Grade I 
No No Alive 
8.CD40 ligand 
T-lymphocyte-
specific 
1.8  F150mg/m2 
Mel140mg/m2 
Al 1mg/kg 
MUD PBSC 34/0/9 Renal cell ca 4.8  No Auto-
immune 
neutron-
penia 
Adeno Alive 
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 221 
T = Treosulfan, F= Fludarabine, Al =Alemtuzumab, Mel = Melphalan, Bu = Busulfan, Cy =Cyclophosphamide, MSD = 222 
matched sibling donor,  UCB = Unrelated Cord Blood, MUD = Matched Unrelated Donor, BM = bone marrow, MMUD 223 
= mismatched unrelated donor, PBSC = Peripheral Blood Stem Cells, ALL = acute lymphocytic leukaemia, JMML = 224 
Juvenile Myelomonocytic Leukemia, AML = Acute Myeloid Leukemia, RMS= Rhabdomyosarcoma, Ca = Carcinoma, 225 
MEC = Mucoepidermoid Carcinoma, T=T Lymphocyte, B=B Lymphocyte, NK= Natural Killer, SCID =Severe 226 
Combined Immunodeficiency, MHC I =Major Histocompatibility Complex I , JAK3= Janus Kinase 3, NFKB2 = Nuclear 227 
Factor Kappa B 2, WAS= Wiskott Aldrich Syndrome, CGD= Chronic Granulomatous Disease, LAD 1= Leukocyte 228 
Adhesion Defect Type 1,HLH= Haemophagocytic Lymphohistiocytosis , GVHD = Graft versus Host Disease 229 
Adeno = Adenovirus, HHV6 = Human Herpes Virus 6, Varicella = Varicella zoster, EBV = Epstein Barr Virus 230 
 231 
 232 
9.T+B+NK low 
SCID 
umknown 
1.0  Bu 12.8mg/kg 
Cy 200mg/kg 
Al  1mg/kg 
MUD BM 96 Whole blood AML 11  No No No Alive 
10.LAD1 
systemic 
1.4  F150mg/m2 
Mel140mg/m2 
Al 1mg/kg 
MUD BM 100/100/100 Renal Cell Ca 11.2  No Immune 
thrombo-
cytopenia 
No Alive 
11.T-B+NK+ 
SCID 
unknown 
4.4  F 150mg/m2 
Mel 140mg/m2 
Al 0.6mg/kg 
MSD BM 100/100/100 Embryonal 
RMS of right 
cheek 
0.45 Acute GVHD- 
Skin Grade 
3,Liver Grade 
2,Gut Grade 2 -
II 
Chronic GVHD 
- gut 
No Adeno 
Varicella 
Alive 
 
12.Griscelli/HLH 
systemic 
0.7  T 42g/m2 
F 150mg/m2 
MSD BM 0 whole blood JMML 0.78 No No Adeno Died 
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Data from the population-based Northern UK Region Young Persons' Malignant 
Disease Registry describe an age-standardized incidence rate of 121 per million per 
year in children aged 0-14 years diagnosed between 1968 and 1995, equating to 0.18% 
of children developing malignancy before their 15th birthday1. The latest UK incidence 
statistics indicate a similar risk of 0.2%2.  A review of post-transplant secondary 
malignancies described its occurrence in up to 7% of recipients by 20 years post-
transplant with no evidence of a plateau with longer follow-up3. Two large international 
registry-based studies describe the cumulative incidence of secondary solid 
malignancies in recipients of allogeneic HSCT for haematological conditions: using 
Kaplan-Meier analysis, invasive secondary solid malignancies (56% of which were not 
Post transplant lymphoproliferative disorders (PTLD)) occurred in 0.9%, 4.3% and 11% 
of 3182 children at 5, 10 and 15 years post-transplant4. More recently, using competing 
risks analysis, the cumulative incidence of secondary non-PTLD solid malignancies was 
3.3% at 20 years post-transplant amongst 28,874 recipients of all ages5. 
A European Bone Marrow Transplantation group survey estimated incidence of 
MDS/AML to be 1.2:1000 transplants, mostly occurring within 4 years of HSCT6. 
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